Esteban R - Search Results

1

PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy.

Papatheodoridis G, Dalekos G, Sypsa V, Yurdaydin C, Buti M, Goulis J, Calleja JL, Chi H, Manolakopoulos S, Mangia G, Gatselis N, Keskin O, Savvidou S, de la Revilla J, Hansen BE, Vlachogiannakos I, Galanis K, Idilman R, Colombo M, Esteban R, Janssen HL, Lampertico P. Papatheodoridis G, et al. Among authors: esteban r. J Hepatol. 2016 Apr;64(4):800-6. doi: 10.1016/j.jhep.2015.11.035. Epub 2015 Dec 8. J Hepatol. 2016. PMID: 26678008

2

Is hepatitis B virus subtype testing useful in predicting virological response and resistance to lamivudine?

Buti M, Cotrina M, Valdes A, Jardi R, Rodriguez-Frias F, Esteban R. Buti M, et al. Among authors: esteban r. J Hepatol. 2002 Mar;36(3):445-6. doi: 10.1016/s0168-8278(01)00283-5. J Hepatol. 2002. PMID: 11867193 No abstract available.

3

Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin.

Buti M, Sanchez-Avila F, Lurie Y, Stalgis C, Valdés A, Martell M, Esteban R. Buti M, et al. Among authors: esteban r. Hepatology. 2002 Apr;35(4):930-6. doi: 10.1053/jhep.2002.32150. Hepatology. 2002. PMID: 11915041 Clinical Trial.

4

Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation.

Castells L, Vargas V, Rodríguez F, Allende H, Buti M, Sánchez-Avila JF, Jardí R, Margarit C, Pumarola T, Esteban R, Guardia J. Castells L, et al. Among authors: esteban r. Liver Transpl. 2002 Oct;8(10):892-900. doi: 10.1053/jlts.2002.35555. Liver Transpl. 2002. PMID: 12360430 Free article.

5

Applicability of real-time PCR combined with melting curve analysis for the study of hepatitis B virus genome mutations.

Rodriguez-Frias F, Jardi R, Buti M, Esteban R. Rodriguez-Frias F, et al. Among authors: esteban r. Hepatology. 2003 Feb;37(2):478-9; author reply 479-80. doi: 10.1053/jhep.2003.50030. Hepatology. 2003. PMID: 12540804 No abstract available.

6

Adefovir dipivoxil.

Buti M, Esteban R. Buti M, et al. Among authors: esteban r. Drugs Today (Barc). 2003 Feb;39(2):127-35. doi: 10.1358/dot.2003.39.2.799419. Drugs Today (Barc). 2003. PMID: 12698207 Review.

7

Extending combination therapy with peginterferon alfa-2b plus ribavirin for genotype 1 chronic hepatitis C late responders: a report of 9 cases.

Buti M, Valdés A, Sánchez-Avila F, Esteban R, Lurie Y. Buti M, et al. Among authors: esteban r. Hepatology. 2003 May;37(5):1226-7. doi: 10.1053/jhep.2003.50107. Hepatology. 2003. PMID: 12717407 Clinical Trial. No abstract available.

8

Entecavir, FTC, L-FMAU, LdT and others.

Buti M, Esteban R. Buti M, et al. Among authors: esteban r. J Hepatol. 2003;39 Suppl 1:S139-42. doi: 10.1016/s0168-8278(03)00316-7. J Hepatol. 2003. PMID: 14708692 Review.

9

Mutations in the basic core promoter region of hepatitis B virus. Relationship with precore variants and HBV genotypes in a Spanish population of HBV carriers.

Jardi R, Rodriguez F, Buti M, Costa X, Valdes A, Allende H, Schaper M, Galimany R, Esteban R, Guardia J. Jardi R, et al. Among authors: esteban r. J Hepatol. 2004 Mar;40(3):507-14. doi: 10.1016/j.jhep.2003.11.015. J Hepatol. 2004. PMID: 15123367

10

Hepatitis C virus Core Antigen as a predictor of non-response in genotype 1 chronic hepatitis C patients treated with peginterferon alpha-2b plus ribavirin.

Buti M, Mendez C, Schaper M, Sauleda S, Valdes A, Rodriguez-Frias F, Jardi R, Esteban R. Buti M, et al. Among authors: esteban r. J Hepatol. 2004 Mar;40(3):527-32. doi: 10.1016/j.jhep.2003.11.026. J Hepatol. 2004. PMID: 15123370

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

631 results

Search Page